GWPH - GW Pharmaceuticals plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
171.00
+1.68 (+0.99%)
As of 9:37AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close169.32
Open166.61
Bid171.00 x 1000
Ask173.50 x 1000
Day's Range169.64 - 170.08
52 Week Range90.14 - 182.23
Volume11,631
Avg. Volume531,540
Market Cap5.229B
Beta (3Y Monthly)3.58
PE Ratio (TTM)N/A
EPS (TTM)-9.42
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est188.17
Trade prices are not sourced from all markets
  • 2 Brand-Name Pot Stocks That Will Lose Money in 2020
    Motley Fool1 hour ago

    2 Brand-Name Pot Stocks That Will Lose Money in 2020

    Being popular within the investment community doesn't mean being profitable.

  • MarketWatch2 hours ago

    GW Pharma announces sale of priority review voucher for $105 million

    GW Pharmaceuticals Plc said Monday it is selling its Rare Pediatric Disease Priority Review Voucher for $105 million. The company, which was the first to receive U.S. Food and Drug Administration approval for a cannabis-based drug, received the PRV when it was developing that treatment called Epidiolex, which treats seizures associated with two types of rare childhood epilepsy. The PRV program aims to encourage companies to invest in R&D for rare pediatric diseases. The buyer is entitled to a priority, expedited review, with the aim of helping to bring drugs to market that treat rare diseases. "The sale of the PRV provides an important source of non-dilutive capital to help advance our pipeline and to continue to invest in the EPIDIOLEX commercial launch in both the U.S. and Europe," GW Pharma Chief Executive Justin Gover said in a statement. Shares were not yet active premarket, but have gained 42.5% in the last 12 months, while the S&P 500 has gained 2.6%.

  • GlobeNewswire2 hours ago

    GW Pharmaceuticals plc Announces the Sale of Priority Review Voucher for $105M

    GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, today announced that GW Research Ltd. has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $105,000,000.  GW was awarded the voucher under a U.S. Food and Drug Administration (FDA) program intended to encourage the development of treatments for rare pediatric diseases. GW Research Ltd. received the PRV when EPIDIOLEX® (cannabidiol) was approved by the FDA for the treatment of seizures associated with Lennox-Gastaut Syndrome or Dravet syndrome, two rare, severe childhood-onset epilepsies.

  • Better Marijuana Stock: Aurora Cannabis vs. GW Pharmaceuticals
    Motley Fool2 days ago

    Better Marijuana Stock: Aurora Cannabis vs. GW Pharmaceuticals

    Which stock wins in a matchup between a top Canadian marijuana producer and a leading cannabinoid drugmaker?

  • Moving Average Crossover Alert: GW Pharmaceuticals
    Zacks3 days ago

    Moving Average Crossover Alert: GW Pharmaceuticals

    GW Pharmaceuticals plc (GWPH) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

  • ACCESSWIRE4 days ago

    Three of the Influential Health and Wellness Cannabis Companies

    Multi-billion-dollar industries are already being uprooted by cannabis, including beverages, alcohol, beer, sports drinks, pharmaceuticals, tobacco, and the $3.2 trillion wellness industry, as the cultural renaissance just gets underway. It's just starting to disrupt countless, multi-billion-dollar industries, especially the $4.2 trillion wellness industry. The Yield Growth Corporation (BOSS)(BOSQF), for example, has engaged the Faculty of Pharmaceutical Sciences at the University of British Columbia (UBC) to identify and quantify anti-inflammatory and other bioactive compounds in its hemp root oil derived by Yield Growth's proprietary extraction methods.

  • ACCESSWIRE6 days ago

    Top Cannabis Plays-THC Therapeutics, Inc

    HENDERSON, NV / ACCESSWIRE / March 12, 2019 / Year to date, the Global Cannabis Stock Index is up almost 50% in less than three months. It's safe to say investors are bullish on the cannabis. Here are ...

  • Has GW Pharmaceuticals (GWPH) Outpaced Other Medical Stocks This Year?
    Zacks7 days ago

    Has GW Pharmaceuticals (GWPH) Outpaced Other Medical Stocks This Year?

    Is (GWPH) Outperforming Other Medical Stocks This Year?

  • The War on Tobacco, E-Cigs, and CBD May Be Coming to an End
    Motley Fool8 days ago

    The War on Tobacco, E-Cigs, and CBD May Be Coming to an End

    Food and Drug Administration Commissioner Scott Gottlieb's resignation has far-reaching implications.

  • Thomson Reuters StreetEvents10 days ago

    Edited Transcript of GWPH.O earnings conference call or presentation 26-Feb-19 9:30pm GMT

    Q4 2018 GW Pharmaceuticals PLC Earnings Call (Transition to 2019 Fiscal Period)

  • The Marijuana Industry: Everything You Need to Know
    Motley Fool12 days ago

    The Marijuana Industry: Everything You Need to Know

    Here are the most important things you should know before investing in pot stocks.

  • ACCESSWIRE12 days ago

    Non-Opioid Treatment Cos. for Investors in Wake of Purdue Pharma News

    HENDERSON, NV / ACCESSWIRE / March 6, 2019 / OxyContin maker Purdue Pharma is exploring filing for bankruptcy as one of its options to address potentially significant liabilities from thousands of lawsuits ...

  • Benzinga13 days ago

    Piper Jaffray: Tilray, GW Pharma Are Early Leaders In Medical Cannabis

    Cannabis stocks have been red-hot so far in 2019, and Piper Jaffray analyst Michael Lavery said Monday that the outlook for medical cannabis is brighter than ever. The medical expert Lavery met with said vapor is the safest and most effective way to deliver cannabis treatment, while tinctures are also effective, with a longer onset period.

  • Top Marijuana Stocks on the NASDAQ
    Investopedia13 days ago

    Top Marijuana Stocks on the NASDAQ

    Although the majority of U.S.-based cannabis companies and many foreign ADRs trade over-the-counter, a few marijuana companies are traded on the NASDAQ. Some investors prefer stocks that are listed on the NASDAQ to other exchanges due to their increased liquidity and tighter spreads than the OTC markets.

  • Zacks13 days ago

    S&P Below 2800 Again after Monday Selloff

    S&P; Below 2800 Again after Monday Selloff

  • 3 Marijuana Stocks to Avoid Like the Plague in March
    Motley Fool13 days ago

    3 Marijuana Stocks to Avoid Like the Plague in March

    To be blunt, these pot stocks are bad news.

  • How the cannabis industry could be worth a trillion dollars in a decade
    Investopedia14 days ago

    How the cannabis industry could be worth a trillion dollars in a decade

    Institutional demand, liquidity, perception and price can turn the cannabis industry into a once in a lifetime investing opportunity.

  • GW, Hasbro, Salesforce, American Express and Intuit highlighted as Zacks Bull and Bear of the Day
    Zacks14 days ago

    GW, Hasbro, Salesforce, American Express and Intuit highlighted as Zacks Bull and Bear of the Day

    GW, Hasbro, Salesforce, American Express and Intuit highlighted as Zacks Bull and Bear of the Day

  • Breakeven On The Horizon For GW Pharmaceuticals plc (NASDAQ:GWPH)
    Simply Wall St.14 days ago

    Breakeven On The Horizon For GW Pharmaceuticals plc (NASDAQ:GWPH)

    GW Pharmaceuticals plc's (NASDAQ:GWPH): GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The US$5.4b market-capRead More...

  • 5 Best Marijuana Stocks in February -- Are They Buys Now?
    Motley Fool14 days ago

    5 Best Marijuana Stocks in February -- Are They Buys Now?

    These marijuana stocks sizzled last month. But will that sizzle fizzle or get even hotter?

  • Bull of the Day: GW Pharmaceuticals (GWPH)
    Zacks14 days ago

    Bull of the Day: GW Pharmaceuticals (GWPH)

    Bull of the Day: GW Pharmaceuticals (GWPH)

  • Why Marijuana Stock GW Pharmaceuticals Jumped 20.5% in February
    Motley Fool15 days ago

    Why Marijuana Stock GW Pharmaceuticals Jumped 20.5% in February

    Initial U.S. sales of the British biopharm's cannabis-derived drug, Epidiolex, were better than expected.

  • Benzinga17 days ago

    Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week

    This week, U.S. lawmakers again introduced legislation that would put an end to the federal prohibition of cannabis, allowing states to decide on their own marijuana policies without the risk of federal interference. The law in question, dubbed The Marijuana Justice Act, was introduced by Rep. Barbara Lee (D-CA) and Sen. Cory Booker (D-NJ), garnering 43 co-sponsors in the House and six others in the Senate in the last session. It is, to date, the “most far-reaching and comprehensive cannabis policy reform legislation being considered in Congress,” explained Morgan Fox, Media Relations Director for the National Cannabis Industry Association.

  • TheStreet.com18 days ago

    Jim Cramer: My Best Stock Picks for Cannabis and China

    People want me to recommend every cannabis stock. No, I won't. I will only recommend Canopy Growth , Cronos Group and GW Pharmaceuticals . People want me to recommend every Chinese stock. No, I won't.

  • New Cannabis Products Which Could Disrupt the Industry in 2019
    Investopedia18 days ago

    New Cannabis Products Which Could Disrupt the Industry in 2019

    The cannabis industry enjoyed tremendous investor enthusiasm in 2018, fueled in large part by major developments which seemed to open up the space for new opportunities. In spite of the fact that cannabis stocks overall failed to perform up to expectations last year, 2019 has already revealed continued anticipation regarding this growing industry. If cannabis stocks are to thrive going forward, it's likely that many companies will have some growing up to do.